EMEDZ.NET

Disclaimer Notice:

Dear Readers! I started this blog when my daughter was in the NICU. She had ventriculitis. Her CSF report grew E.coli. But, she was injected Teicoplanin directly into her brain. The doctors made two errors here:

Teicoplanin is for gram-positive bacteria only. It does not treat E.coli.
Teicoplanin is not for intraventricular use. The manufacturer strongly discourage injecting Teicoplanin into the brain.

My daughter bled into the brain. She lived for another two years and ultimately died.

The information provided on Emedz.net is for doctors and pharmacists only to manage their patients in the best way and avoid medications-related errors.

Still, for the general population, this should not be considered professional medical advice or a substitute for consultation with a licensed healthcare provider. The content on this blog is not intended to diagnose, treat, cure, or prevent any disease or health condition.

Always seek the advice of a qualified healthcare professional before making any changes to your diet, exercise routine, medication, or any other aspect of your healthcare. We strongly discourage self-medication and self-treatment.

Even though the primary author of emedz.net is an experienced health professional, the blog is not intended to replace medical advice sought at the Doctor’s Clinic.

The authors share personal experiences, research findings, and general knowledge about health and wellness and medications-related topics.

However, individual health situations vary, and what works for one person may not work for another. It's important to consult with a healthcare provider for personalized guidance.

We strive to provide accurate and up-to-date information, but medical knowledge is constantly evolving. Therefore, we do not guarantee the accuracy, completeness, or timeliness of the information presented in this blog.

Emedz.net is not an online pharmacy:

Online pharmacies sell medicines and pharmaceutical products. EMEDZ.net is intended to provide drug-related information to pharmacists and physicians. It is intended to provide authentic information about medicines so as to prevent errors related to prescriptions.

We do not sell medicines, so please don’t ask for them.

We are not affiliated with any pharmaceutical companies:

Emedz.net has no affiliation with any pharmaceutical companies. We do not promote any product. Sometimes brand names are also mentioned in the title of the page, but that is what is called a “Featured Image”. It has nothing to do with selling or promoting that brand. Just to make things easier, generic and brands are mentioned in the blog.

Emedz.net may contain links to external websites or resources for your convenience. We do not endorse or take responsibility for the content of these external sites.

In no event shall Emedz.net, its authors, contributors, or any related parties be liable for any damages or consequences arising from the use of the information provided on this blog.

By using Emedz.net, you acknowledge and agree to this disclaimer and our Terms of Use. If you do not agree with this disclaimer or our Terms of Use, we advise you to refrain from using our website.

Remember, your health is a valuable asset, and decisions about your health should always be made in consultation with a qualified healthcare professional.

Alimemazine (Trimeprazine) - Drug Information

Trimeprazine is a medication primarily used in veterinary medicine. It belongs to a class of drugs known as phenothiazine derivatives, which have various effects including sedation, antiemetic (preventing vomiting), and antihistaminic properties (reducing allergic reactions). In veterinary practice, trimeprazine is often used as an antihistamine to alleviate itching and allergic reactions in dogs and cats, and it may also be used as a sedative for calming anxious or agitated animals.

Alimemazine (Trimeprazine) is a Phenothiazine derivative that has enhanced antipruritic and antihistaminic effects with reduced central effects.

It is used in the symptomatic treatment of cough and pruritis.

Trimeprazine Dose in Adults

Alimemazine dose in the treatment of Cough and pruritus:

When starting, it's best to begin with a small amount and adjust as needed.
For oral use, typically it's given as 2.5 mg to 5 mg twice a day after meals, and another 5 mg at bedtime.
Or, it could be given as 5 mg to 10 mg just once at bedtime.
In severe cases of itching, for pets in the hospital, doses up to 80 mg a day, spread throughout the day, may be considered under close supervision.

Trimeprazine Dose in Children

Trimeprazine Dose in the treatment of Cough and pruritus:

Note: When starting, it's best to begin with a small amount and adjust as needed.

For children aged 2 to 12 years:

The usual starting dose is 2.5 mg to 5 mg once a day at bedtime.
If necessary, an extra dose of 2.5 mg can be given twice daily after meals.
The maximum dose for children is 15 mg per day.

Adolescents:

Adolescents should follow the dosing for adults.

Pregnancy Risk factor: C

Animal studies have not shown any negative effects on pregnancy or reproduction.

Trimeprazine use during breastfeeding:

Phenothiazines, a group of drugs that includes trimeprazine, can be passed into human breast milk, but we're not sure if trimeprazine specifically does this.

Trimeprazine Dose in Renal Disease:

The manufacturer's instructions do not include any specific changes to the dosage for people with kidney problems.

Trimeprazine Dose in Liver Disease:

The manufacturer's instructions do not mention any changes to the dosage for individuals with liver problems.

Side effects of Alimemazine (Trimeprazine):

Cardiovascular:
- Cardiac Arrhythmia
- ECG Changes
- Syncope
- Torsades De Pointes
Central Nervous System:
- Akathisia
- Depression
- Drowsiness (Dose Related)
- Dystonia
- Mood Elevation
- Nightmares
- Parkinsonian-Like Syndrome
- Seizure
- Tardive Dyskinesia
Gastrointestinal:
- Abdominal Distress
- Gastric Distress
- Nausea
- Xerostomia
Hepatic:
- Cholestatic Jaundice
Neuromuscular & Skeletal:
- Dyskinesia (Transient)
- Neuromuscular Reaction
Respiratory:
- Nasal Congestion

Contraindication to Trimeprazine Include:

Trimeprazine should not be used if there's a history of severe allergic reactions to trimeprazine itself, any of its ingredients, or other drugs in the phenothiazine family.
It's also not suitable if there's a history of blood disorders linked to trimeprazine or other phenothiazines, or if there's a state of central nervous system depression caused by barbiturates, alcohol, opioids, or painkillers.
Additionally, it's not recommended for children under 2 years of age.

Warnings and precautions

Modified cardiac conduction

Trimeprazine can affect the way the heart beats by changing its conduction.
This might show up on an ECG (electrocardiogram) as changes in the QT interval, ST depression, or alterations in T or U waves.
In some cases, it can lead to serious heart rhythm problems like atrioventricular (AV) block, supraventricular tachycardia, ventricular tachycardia, and fibrillation.
This risk may be higher in elderly patients, those with heart disease, low potassium levels, or those taking tricyclic antidepressants at the same time.
Rarely, it can lead to severe heart rhythm disturbances like torsades de pointes, ventricular fibrillation, cardiac arrest, and sudden death.

CNS depression:

Trimeprazine can lead to central nervous system (CNS) depression, potentially affecting both physical and mental abilities.
Patients should be warned about activities requiring mental alertness, such as operating machinery or driving, while taking this medication.
Drowsiness is a common side effect, but it may lessen within 1 to 3 weeks.
However, elderly individuals and those taking doses equal to or greater than 30 mg per day might experience drowsiness more frequently.
Starting treatment with a lower dose and gradually increasing it can help minimize drowsiness.

Extrapyramidal effects:

Trimeprazine can lead to extrapyramidal symptoms, affecting movements and muscle control, such as tremors, muscle stiffness, painful muscle contractions, abnormal muscle movements (dystonia), restlessness (akathisia), and tardive dyskinesia.
These effects may be related to the dose or how long the medication is taken.
Acute reactions might occur within 4 days in children and young adults, while symptoms like Parkinsonism could develop weeks or months after starting treatment in adults and the elderly.
If neuromuscular reactions occur, the medication should be stopped immediately, especially in children or pregnant women, with no restart.
For other patients, restarting therapy may be considered at a lower dose.

Hepatic impairment

Trimeprazine should be used cautiously in patients with liver problems or jaundice.

Seizures:

Trimeprazine should be used cautiously in patients who are at risk of seizures, such as those with a history of seizures or seriously ill or dehydrated children.

Trimeprazine (alimemazine): Drug Interaction

Risk Factor C (Monitor therapy)
Acetylcholinesterase Inhibitors	May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.
Alcohol (Ethyl)	Alcohol's CNS depressing impact may be amplified by CNS depressants (Ethyl).
Alizapride	CNS depressants may have an enhanced CNS depressant impact.
Amantadine	may strengthen an anticholinergic agent's anticholinergic action.
Amezinium	Antihistamines may intensify Amezinium's stimulant effects.
Amphetamines	may lessen antihistamines' sedative effects.
Anticholinergic Agents	Other anticholinergic agents' negative or hazardous effects could be amplified.
ARIPiprazole	ARIPiprazole's serum levels may rise in response to trimeprazine.
Betahistine	Antihistamines may diminish the therapeutic effect of Betahistine.
Botulinum Toxin-Containing Products	May enhance the anticholinergic effect of Anticholinergic Agents.
Brexanolone	CNS Depressants may enhance the CNS depressant effect of Brexanolone.
Brimonidine (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Bromopride	May enhance the CNS depressant effect of CNS Depressants.
Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Cannabis	May enhance the CNS depressant effect of CNS Depressants.
Chloral Betaine	May enhance the adverse/toxic effect of Anticholinergic Agents.
Chlorphenesin Carbamate	May enhance the adverse/toxic effect of CNS Depressants.
CNS Depressants	Trimeprazine may enhance the CNS depressant effect of CNS Depressants.
Dimethindene (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Doxylamine	May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended.
Dronabinol	May enhance the CNS depressant effect of CNS Depressants.
Esketamine	May enhance the CNS depressant effect of CNS Depressants.
Gastrointestinal Agents (Prokinetic)	Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic).
Glucagon	Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.
HydrOXYzine	May enhance the CNS depressant effect of CNS Depressants.
Itopride	Anticholinergic Agents may diminish the therapeutic effect of Itopride.
Kava Kava	May enhance the adverse/toxic effect of CNS Depressants.
Lofexidine	May enhance the CNS depressant effect of CNS Depressants. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.
Magnesium Sulfate	May enhance the CNS depressant effect of CNS Depressants.
MetyroSINE	CNS Depressants may enhance the sedative effect of MetyroSINE.
Mianserin	May enhance the anticholinergic effect of Anticholinergic Agents.
Minocycline	May enhance the CNS depressant effect of CNS Depressants.
Mirabegron	Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.
Mirtazapine	CNS Depressants may enhance the CNS depressant effect of Mirtazapine.
Nabilone	May enhance the CNS depressant effect of CNS Depressants.
Nitroglycerin	Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption.
Piribedil	CNS Depressants may enhance the CNS depressant effect of Piribedil.
Pramipexole	CNS Depressants may enhance the sedative effect of Pramipexole.
Ramosetron	Anticholinergic Agents may enhance the constipating effect of Ramosetron.
ROPINIRole	CNS Depressants may enhance the sedative effect of ROPINIRole.
Rotigotine	CNS Depressants may enhance the sedative effect of Rotigotine.
Rufinamide	May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.
Selective Serotonin Reuptake Inhibitors	CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.
Tetrahydrocannabinol	May enhance the CNS depressant effect of CNS Depressants.
Tetrahydrocannabinol and Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Thiazide and Thiazide-Like Diuretics	Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics.
Topiramate	Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.
Risk Factor D (Consider therapy modification)
Benzylpenicilloyl Polylysine	Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.
Blonanserin	CNS Depressants may enhance the CNS depressant effect of Blonanserin.
Buprenorphine	CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.
Chlormethiazole	May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.
Droperidol	May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Exceptions to this monograph are discussed in further detail in separate drug interaction monographs.
Flunitrazepam	CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.
Hyaluronidase	Antihistamines may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.
HYDROcodone	CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Methotrimeprazine	CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.
Opioid Agonists	CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
OxyCODONE	CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Perampanel	May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.
Pramlintide	May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.
Secretin	Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.
Sodium Oxybate	May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.
Suvorexant	CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.
Tapentadol	May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Zolpidem	CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.
Risk Factor X (Avoid combination)
Aclidinium	May enhance the anticholinergic effect of Anticholinergic Agents.
Azelastine (Nasal)	CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).
Bromperidol	May enhance the CNS depressant effect of CNS Depressants.
Cimetropium	Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium.
Eluxadoline	Anticholinergic Agents may enhance the constipating effect of Eluxadoline.
Glycopyrrolate (Oral Inhalation)	Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation).
Glycopyrronium (Topical)	May enhance the anticholinergic effect of Anticholinergic Agents.
Ipratropium (Oral Inhalation)	May enhance the anticholinergic effect of Anticholinergic Agents.
Levosulpiride	Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride.
Orphenadrine	CNS Depressants may enhance the CNS depressant effect of Orphenadrine.
Oxatomide	May enhance the anticholinergic effect of Anticholinergic Agents.
Oxomemazine	May enhance the CNS depressant effect of CNS Depressants.
Paraldehyde	CNS Depressants may enhance the CNS depressant effect of Paraldehyde.
Pitolisant	Antihistamines may diminish the therapeutic effect of Pitolisant.
Potassium Chloride	Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.
Potassium Citrate	Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.
Revefenacin	Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin.
Thalidomide	CNS Depressants may enhance the CNS depressant effect of Thalidomide.
Tiotropium	Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.
Umeclidinium	May enhance the anticholinergic effect of Anticholinergic Agents.

Monitor:

Monitoring Mental Status and Vital Signs

Keep an eye on mental alertness and behavior.
Check vital signs like heart rate, blood pressure, and temperature as needed, especially if there are concerns about the patient's health.

How to administer Alimemazine (Trimeprazine, Penectyl)?

Taking Trimeprazine Orally

Trimeprazine can be taken with or without food.
Taking it after meals might help decrease the chance of side effects.

Mechanism of action of Alimemazine (Trimeprazine, Panectyl):

Trimeprazine is a type of phenothiazine derivative.
It has fewer effects on the central nervous system compared to other drugs in this class.
It's particularly effective at relieving itching and allergic reactions.
Trimeprazine also works well as a sedative, antiemetic (reduces vomiting), antispasmodic (reduces muscle spasms), and against serotonin-related issues.
Its impact on the autonomic nervous system is relatively low.

Absorption:

Trimeprazine absorption is slowed down when taken with food.

Distribution:

More than 90% of trimeprazine binds to plasma proteins.

Bioavailability:

When taken in tablet form, less than 70% of trimeprazine is absorbed into the body.

Half-life, elimination:

Trimeprazine has an elimination half-life of about 4.78 hours, indicating how long it takes for half of the drug to leave the body.

Time to peak serum concentration:

For tablets, it takes around 4.5 hours for trimeprazine to reach its highest concentration in the bloodstream after being taken.

International Brands of Trimeprazine:

Panectyl

Trimeprazine Brands in Pakistan":

No Brands Available in Pakistan.

Alimemazine (Trimeprazine) - Drug Information

Recent Posts

Related Posts